Navigation Links
Two Studies Evaluated Full-Dose Chemotherapy Regimen and Concurrent Radiation in Treatment of Lung Cancer
Date:5/20/2010

INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Results of two Phase II trials evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., on June 6, 2010.

The standard of care for many patients with unresectable stage IIIA/B NSCLC is a concurrent treatment of chemotherapy and radiation, but the chosen chemotherapy varies by oncologist.  Previous study results for an ALIMTA-based regimen in this therapeutic area warranted further study.(1)

The Phase II study (ASCO Abstract #7087) evaluated 39 patients with unresectable stage IIIA/B NSCLC who were treated with full doses of ALIMTA and cisplatin and a full dose of concurrent radiation. Patients on the ALIMTA regimen achieved a median overall survival of 19.7 months and median progression-free survival of 11.8 months.  Eighty percent of patients continued to live one year following initial treatment and 47 percent of patients were living for one year without tumor progression.  The single-arm trial accrued patients across five centers in Canada.  

Ten patients experienced grade 3/4 hematologic toxicity, particularly neutropenia (low white blood cell count).  Non-hematologic toxicities were also observed, including grade 3 nausea/vomiting, espohagitis (inflammation of the esophagus), serum sodium and potassium alterations, fatigue, and pneumonitis (inflammation of lung tissue) and grade 4 hypotension (low blood pressure).

"Early results from th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data From LigoCytes Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
2. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
3. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
4. US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
5. Data From Three Clinical Studies of bioTheranostics Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
6. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
7. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
8. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
9. Nplate(R) Data From MDS Studies Presented at ASH
10. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
11. Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ), ... small molecule drugs for the treatment of cancer and ... host a conference call and live audio webcast on ... the company,s second quarter fiscal 2011 financial and operational ...
... Health today announced that its board of directors has approved a ... to shareholders of record on April 1. This marks the 106th ... Cardinal Health Headquartered in Dublin, Ohio, Cardinal ... health care services company that improves the cost-effectiveness of ...
Cached Medicine Technology:Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011 2Cardinal Health Declares Regular Quarterly Dividend 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CITY, Iowa, May 6 Quatro Composites, ... composite products, has been,awarded ISO 9001:2000 and ... of its facilities, located in Orange City, ... of the AS9100 quality management,system., "Receiving ...
... 20% Year-Over-Year ... Cost Reduction Efforts Show ... Ends the Quarter with $10.5 Million in Cash, MONROVIA, Calif., May ... and marketer of,minimally invasive ophthalmic products, today reported good progress during,its first ...
... finds short-term dysfunction while awaiting operation rarely turns ... -- Few patients who have short-term kidney dysfunction ... problems once they have their transplant, says a ... have kidney dysfunction while awaiting liver transplantation, which ...
... Demonstrate to Protect Their Voice & Vote at,SEIU Hearing, ... the direction of the Service Employees International Union (SEIU),intensified ... was held to,determine the fate of more than 60,000 ... West (UHW). UHW represents 150,000,caregivers in hospitals, clinics, nursing ...
... Management: Making a ... Difference Today and Tomorrow, HARRISBURG, Pa., ... Officer, will deliver the clinical keynote,address on Wednesday afternoon, May ... World of Care Management. Dr. Petrulis will,present Care Management: Making ...
... aid couples trying to conceive , , TUESDAY, May 6 ... the lubricant they use wisely because some lubricants can ... commercial lubricants are toxic to sperm, and couples who ... they want," said study author Dr. William H. Kutteh, ...
Cached Medicine News:Health News:Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification 2Health News:STAAR Surgical Reports Solid First Quarter Progress 2Health News:STAAR Surgical Reports Solid First Quarter Progress 3Health News:STAAR Surgical Reports Solid First Quarter Progress 4Health News:STAAR Surgical Reports Solid First Quarter Progress 5Health News:STAAR Surgical Reports Solid First Quarter Progress 6Health News:STAAR Surgical Reports Solid First Quarter Progress 7Health News:STAAR Surgical Reports Solid First Quarter Progress 8Health News:STAAR Surgical Reports Solid First Quarter Progress 9Health News:STAAR Surgical Reports Solid First Quarter Progress 10Health News:STAAR Surgical Reports Solid First Quarter Progress 11Health News:STAAR Surgical Reports Solid First Quarter Progress 12Health News:Kidney Trouble Short-Lived in Most Liver Transplant Patients 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 3
... growth factor I (IGF-I or somatomedin C) is ... liver. It acts as a potent mitogen of ... specific cell-surface receptors. In the circulation, IGF-I is ... regulate the actions of IGF-I by modulating the ...
... potent naturally occurring androgen produced from ... 5a-reductase [1]. The concentrations of ... tissues, including genital skin and hair ... apparent association with the nuclear membrane. ...
Urovac bladder evacuator with adaptor...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Medicine Products: